Cytovance Biologics Appoints Ping Zhang as CEO

Cytovance Biologics, a biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian and microbial biologics, has appointed Ping Zhang as chief executive officer.
 
In his role as CEO, Zhang provides oversight in the development and execution of the company’s business strategies in the contract manufacturing industry. He holds a Master of Business Administration and serves on the board of other subsidiaries within the Hepalink Group.
 
Zhang has over 30 years of experience in manufacturing and operations in the pharmaceutical industry. He served at Sanofi as the Head of Industry Affairs China for 20 years and was responsible for seven plants across China. Zhang has extensive experience in technical transfer and new product launch at Sanofi China. Prior to that, he served as the Head of Manufacturing at Johnson & Johnson China for 14 years.
 
“At Cytovance, everything we do here is driven by our mission and responsibility to our customers who use our products and services to enable the world to be a healthier, safer, and better place.” said Zhang. “As a biologics CDMO that focuses on development and manufacturing for more than 20 years, we are constantly striving to provide value to customers and patients.”